News articles about ZIOPHARM Oncology (NASDAQ:ZIOP) have trended somewhat negative recently, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. ZIOPHARM Oncology earned a coverage optimism score of -0.01 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.6433148807266 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

NASDAQ ZIOP traded up $0.07 during trading on Tuesday, hitting $3.00. The stock had a trading volume of 10,449 shares, compared to its average volume of 1,560,503. The company has a market cap of $407.21 million, a P/E ratio of -5.64 and a beta of 1.33. ZIOPHARM Oncology has a one year low of $2.23 and a one year high of $6.67.

ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.12). research analysts predict that ZIOPHARM Oncology will post -0.5 earnings per share for the current fiscal year.

A number of research analysts recently commented on the stock. BidaskClub raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. ValuEngine raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Zacks Investment Research downgraded shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, May 16th. HC Wainwright reissued a “buy” rating and issued a $5.50 price objective on shares of ZIOPHARM Oncology in a research note on Monday, May 14th. Finally, JPMorgan Chase & Co. downgraded shares of ZIOPHARM Oncology from a “neutral” rating to an “underweight” rating in a research note on Monday, June 18th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $5.25.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.

Featured Article: Do closed-end mutual funds pay dividends?

Insider Buying and Selling by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with's FREE daily email newsletter.